CA2405551A1 - Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37 - Google Patents

Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37 Download PDF

Info

Publication number
CA2405551A1
CA2405551A1 CA002405551A CA2405551A CA2405551A1 CA 2405551 A1 CA2405551 A1 CA 2405551A1 CA 002405551 A CA002405551 A CA 002405551A CA 2405551 A CA2405551 A CA 2405551A CA 2405551 A1 CA2405551 A1 CA 2405551A1
Authority
CA
Canada
Prior art keywords
cell
gene
cells
tumor
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405551A
Other languages
English (en)
Inventor
Dennis J. Slamon
Juliana J. Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405551A1 publication Critical patent/CA2405551A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'identification du gène suppresseur de tumeur H37 ainsi que des procédés permettant de diagnostiquer et de traiter une maladie ou un trouble caractérisé par une prolifération cellulaire anomale, tel qu'une tumeur ou un cancer. Un diagnostic s'effectue en examinant ou contrôlant des cellules en ce qui concerne des perturbations dans l'expression ou la fonction de H37. Le traitement s'effectue par insertion d'un vecteur d'expression H37 ou d'une quantité efficace de protéine H37 compatible avec une cellule hôte dans au moins une cellule nécessitant un traitement.
CA002405551A 2000-04-19 2001-04-12 Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37 Abandoned CA2405551A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55324200A 2000-04-19 2000-04-19
US09/553,242 2000-04-19
PCT/US2001/012332 WO2001081629A1 (fr) 2000-04-19 2001-04-12 Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37

Publications (1)

Publication Number Publication Date
CA2405551A1 true CA2405551A1 (fr) 2001-11-01

Family

ID=24208693

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405551A Abandoned CA2405551A1 (fr) 2000-04-19 2001-04-12 Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37

Country Status (3)

Country Link
AU (1) AU2001259076A1 (fr)
CA (1) CA2405551A1 (fr)
WO (1) WO2001081629A1 (fr)

Also Published As

Publication number Publication date
AU2001259076A1 (en) 2001-11-07
WO2001081629A1 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
Tran et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer
EP0991421B1 (fr) Detection et modulation d'inhibiteurs de proteines d'apoptose (iap) et de polypeptides anti-apoptotiques apparentes (miap) permettant d'effectuer le diagnostic et le traitement de maladies proliferatives
US7153700B1 (en) Methods and compositions for diagnosing and predicting the behavior of cancer
US7902165B2 (en) Use of AIM3 acting as a tumor suppressor
US7432050B2 (en) Methods and compositions for detecting colon cancers
US8846629B2 (en) Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma
Carbone et al. The molecular genetics of lung cancer
EP2201112A2 (fr) Méthodes pour identifier une interaction du gène "fragile histidine triad" (fhit) et utilisations associées
Vega et al. p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer
JP2005521418A (ja) ヒト・リボヌクレオチド還元酵素ｍ２サブユニット
Pio et al. αCP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant αCP-4a, is underexpressed in lung cancer
Konishi et al. Identification of frequent G2 checkpoint impairment and a homozygous deletion of 14-3-3ε at 17p13. 3 in small cell lung cancers
US7153657B2 (en) Diagnosis and treatment of tumor-suppressor associated disorders
US20100311045A1 (en) Cancer
US7776519B2 (en) Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
US6929910B2 (en) Diagnostic and therapeutic methods using the H37 tumor suppressor gene
CA2405551A1 (fr) Methodes diagnostique et therapeutique mettant en oeuvre le gene suppresseur de tumeur h37
US6753418B2 (en) Suppressors of human breast cancer cell growth
US20030087243A1 (en) Diagnosis, prognosis and treatment of cancer related to the Barx2 gene
ES2395121T3 (es) Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM
Shivakumar et al. Characterization of a Putative Tumor Suppressor in Breast Cancer
WO1999015544A1 (fr) SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES DU GENE brx ET PRODUIT GENIQUE DE CE DERNIER ET UTILISATIONS
White Dallas, Texas 75390-9105
White et al. Isolation of Factors that Disrupt Critical Protein
Arap The biological role of the CDKN2A gene in the progression of human malignant gliomas

Legal Events

Date Code Title Description
FZDE Discontinued